Accurate Diagnosis Of Breast Cancer Research Articles

Diagnostic value of 5 miRNAs combined detection for breast cancer.

Breast cancer (BC) is the prevailing malignant tumor, with its prevalence and death rate steadily rising over time. BC often does not show obvious symptoms in its early stages and is difficult to distinguish from benign breast disease. We aimed to find a distinct group of miRNAs utilizing serum as a non-invasive biomarker for early BC diagnosis. Herein, we mainly include the screening stage, testing stage, and verification stage. In the screening stage, 8 miRNAs associated with BC were selected and analyzed via literature reading, and the expression of the above miRNAs in BC was further verified by bioinformatics and included in the research analysis. In the testing phase, quantitative reverse transcription polymerase chain reaction (qRT-PCR) was deployed to select the five miRNAs with the most significant expression differences in 15 BC patients and 15 benign breast controls to proceed to the next stage. In a subsequent validation phase, the five miRNAs obtained from serum samples from an additional 75 BC patients and 50 benign control patients were evaluated using RT-qPCR. The diagnostic capacity, specificity, and sensitivity of candidate miRNAs were estimated with the receiver operating characteristic (ROC) curve and area under the curve (AUC). Finally, the optimal diagnostic combination model with high sensitivity and strong specificity was constructed by using the above 5 miRNAs. The BC patients reported a significant decline in mir-10b-5p, mir-133a-3p, mir-195-5p, and mir-155-3p levels in serum levels contrasted with those in benign controls. Additionally, BC patients experienced elevated mir-195-3p levels than in benign controls. We implemented ROC analysis to evaluate its diagnostic capacity for BC. We demonstrated that all five miRNAs had robust diagnostic capability, with an AUC above 0.8. We developed a conclusive diagnostic combination model consisting of these 5 miRNAs in order to enhance the diagnosis accuracy. This model demonstrated a high diagnostic value, as shown by an AUC of 0.948. The serum biomarker panels composed of five miRNAs identified in this study (mir-10b-5p, mir-133a-3p, mir-195-5p, mir-195-3p, and mir-155-3p) provide hope for early, non-invasive, and accurate diagnosis of BC.

Optimizing Deep Learning Models with Custom ReLU for Breast Cancer Histopathology Image Classification

Purpose: The prompt identification of breast cancer is crucial in preventing the considerable damage inflicted by this dangerous form of cancer, which is widely distributed across the globe. This study seeks to refine the efficacy of a deep learning-driven approach for the precise diagnosis of breast cancer by employing diverse bespoke Rectified Linear Units (ReLU) to improve the model's performance and reduce inaccuracies within the system. Method: This study focuses on analyzing a deep learning approach utilizing the BreakHis dataset with 7,909 images, incorporating changes to the ReLU activation function across different pre-trained CNN models. It then evaluates performance through measures such as accuracy, precision, recall, and F1-Score. Result: Based on our experiment results, show that the DenseNet201 models with a custom LeakyReLU excel beyond the typical ReLU, achieving the highest accuracy, recall, and F1-Score at 99.21%, 99.21%, and 99.11%, respectively. Simultaneously, ResNet152, utilizing LessNegativeReLU ( ), achieved the highest precision at 99.11%. The VGG11 model exhibited the most notable performance enhancement, with improvements ranging from 1.39% to 1.59%. Novelty: The research is original in optimizing a model for accurate breast cancer diagnosis. The proposed model is superior to the model utilizing the default activation function. This finding indicates that the study significantly enhances performance while effectively minimizing errors, thereby necessitating further exploration into the effectiveness of the customized activation function when applied to other medical imaging modalities.

Mises-Fisher similarity-based boosted additive angular margin loss for breast cancer classification

To enhance the accuracy of breast cancer diagnosis, current practices rely on biopsies and microscopic examinations. However, this approach is known for being time-consuming, tedious, and costly. While convolutional neural networks (CNNs) have shown promise for their efficiency and high accuracy, training them effectively becomes challenging in real-world learning scenarios such as class imbalance, small-scale datasets, and label noises. Angular margin-based softmax losses, which concentrate on the angle between features and classifiers embedded in cosine similarity at the classification layer, aim to regulate feature representation learning. Nevertheless, the cosine similarity’s lack of a heavy tail impedes its ability to compactly regulate intra-class feature distribution, limiting generalization performance. Moreover, these losses are constrained to target classes when margin penalties are applied, which may not always optimize effectiveness. Addressing these hurdles, we introduce an innovative approach termed MF-BAM (Mises-Fisher Similarity-based Boosted Additive Angular Margin Loss), which extends beyond traditional cosine similarity and is anchored in the von Mises-Fisher distribution. MF-BAM not only penalizes the angle between deep features and their corresponding target class weights but also considers angles between deep features and weights associated with non-target classes. Through extensive experimentation on the BreaKHis dataset, MF-BAM achieves outstanding accuracies of 99.92%, 99.96%, 100.00%, and 98.05% for magnification levels of ×40, ×100, ×200, and ×400, respectively. Furthermore, additional experiments conducted on the BACH dataset for breast cancer classification, as well as on the LFW and YTF datasets for face recognition, affirm the generalization capability of our proposed loss function.

Optimizing breast cancer diagnosis: Harnessing the power of nature-inspired metaheuristics for feature selection with soft voting classifiers

Breast cancer is a widespread and serious condition that poses a significant threat to women's health globally, contributing significantly to mortality rates. Machine learning tools play a critical role in both the effective management and early detection of this disease. Feature selection (FS) methods are essential for identifying the most impactful features to improve breast cancer diagnosis. These methods reduce data dimensionality, eliminate irrelevant information, enhance learning accuracy, and improve the comprehensibility of results. However, the increasing complexity and dimensionality of cancer data pose substantial challenges to many existing FS methods, thereby reducing their efficiency and effectiveness. To overcome these challenges, numerous studies have demonstrated the success of nature-inspired optimization (NIO) algorithms across various domains. These algorithms excel in mimicking natural processes and efficiently solving complex optimization problems. Building on these advancements, we propose an innovative approach that combines powerful feature selection methods based on NIO techniques with a soft voting classifier. The NIO techniques employed include the Genetic Algorithm, Cuckoo Search, Salp Swarm, Jaya, Flower Pollination, Whale Optimization, Sine Cosine, Harris Hawks, and Grey Wolf Optimization algorithms. The Soft Voting Classifier integrates various machine learning models, including Support Vector Machines, Gaussian Naive Bayes, Logistic Regression, Decision Tree, and Gradient Boosting. These are used to improve the effectiveness and accuracy of breast cancer diagnosis. The proposed approach has been empirically evaluated using a variety of evaluation measures, such as F1 score, precision, recall, accuracy and Area Under the Curve (AUC), for performance comparison with individual machine learning techniques. The results demonstrate that the soft-voting ensemble technique, particularly when combined with feature selection based on the Jaya algorithm, outperforms all individual classifiers on the breast cancer dataset. It achieves the highest scores for accuracy, precision, recall, F1-score, and AUC, with values of 99.6 %, 99.21 %, 100 %, 99.6 %, and 99.6 %, respectively. Following closely, both the Genetic Algorithm and Salp Swarm feature selection demonstrate strong performance, with scores of 99.5 %, 100 %, 99 %, 99.5 %, and 99.5 %, respectively. Furthermore, the approach's effectiveness in identifying the minimal set of relevant features has been evaluated. Given the critical importance of selecting relevant features in complex cancer datasets, the proposed method proves to be a valuable tool for achieving early detection and improved interpretability. This method can also support healthcare professionals in making well-informed decisions regarding cancer diagnosis and treatment strategies.

AI-Driven Elastography Image Analysis for Accurate Breast Cancer Diagnosis

AI-Driven Elastography Image Analysis for Accurate Breast Cancer Diagnosis

Breast Cancer Diagnosis Utilizing Artificial Neural Network (ANN) Algorithm for Integrating Multi-Omics Data and Clinical Features

Breast cancer is one of the most common diseases affecting women worldwide, with a significant impact on patient's health and quality of life. Despite advances in medical technology and research, breast cancer diagnosis remains a challenge due to its complexity involving various biological and clinical factors. Several previous studies have focused on detecting this disease with optimal accuracy, but the selection of appropriate algorithms and methods is key to achieving this goal. This study aims to improve the accuracy of breast cancer diagnosis by using the ANN algorithm and data balancing method, SMOTE. This research uses Multi-Omic data and Clinical Features obtained in general from Kaggle. The research process is carried out in several stages, namely Data Collection, Preprocessing, Oversampling, Modeling, and Evaluation. This research successfully obtained an increase in accuracy, which was able to achieve an accuracy of 99.30%. This research shows that early detection of breast cancer with ANN algorithm and data balancing using SMOTE can improve accuracy performance in early detection of breast cancer. Given the use of data in this study is not too large, it is recommended for further research to use a larger dataset to validate the strength of the model that has been built on more varied data.

Age‑integrated breast imaging reporting and data system assessment model to improve the accuracy of breast cancer diagnosis.

Early diagnosis is an effective strategy for decreasing breast cancer mortality. Ultrasonography is one of the most predominant imaging modalities for breast cancer owing to its convenience and non-invasiveness. The present study aimed to develop a model that integrates age with Breast Imaging Reporting and Data System (BI-RADS) lexicon to improve diagnostic accuracy of ultrasonography in breast cancer. This retrospective study comprised two cohorts: A training cohort with 975 female patients from Renmin Hospital of Wuhan University (Wuhan, China) and a validation cohort with 500 female patients from Maternal and Child Health Hospital of Hubei Province (Wuhan, China). Logistic regression was used to construct a model combining BI-RADS score with age and to determine the age-based prevalence of breast cancer to predict a cut-off age. The model that integrated age with BI-RADS scores demonstrated the best performance compared with models based solely on age or BI-RADS scores, with an area under the curve (AUC) of 0.872 (95% CI: 0.850-0.894, P<0.001). Furthermore, among participants aged <30 years, the prevalence of breast cancer was lower than the lower limit of the reference range (2%) for BI-RADS subcategory 4A lesions but within the reference range for BI-RADS category 3 lesions, as indicated by linear regression analysis. Therefore, it is recommended that management for this subset of participants are categorized as BI-RADS category 3, meaning that biopsies typically indicated could be replaced with short-term follow-up. In conclusion, the integrated assessment model based on age and BI-RADS may enhance accuracy of ultrasonography in diagnosing breast lesions and young patients with BI-RADS subcategory 4A lesions may be exempted from biopsy.

Advancing Breast Cancer Diagnosis: The Impact of Elastography Integration Into Breast Imaging Reporting and Data System (BIRADS) Categorization.

This study evaluates the impact of integrating elastography into the Breast Imaging Reporting and Data System (BIRADS) categorization on breast cancer diagnostics in an African population. It explores the association and agreement between traditional BIRADS and those modified by elastography, as well as between quantitative and qualitative elastography methods. A total of 200 participants who underwent breast imaging as part of their diagnostic evaluation for breast lesions were included in the study. Participant characteristics, including age distribution and indicators for breast cancer diagnoses, were analyzed. Brightness mode (B-mode) findings without elastography were assessed using the BIRADS classification. Elastography was integrated into the BIRADS categorization to evaluate its impact on breast cancer diagnostics.The association and agreement between BIRADS with and without elastography were analyzed. Participants predominantly aged 40-49 showed significant staging differences with the integration of elastography. Traditional B-mode staging identified 29 (49%) of participants in BIRADS stage IV and 14 (23%) in stage V, whereas elastography adjusted these figures significantly, enhancing diagnostic refinement. There was a fair agreement between BIRADS with and without elastography (kappa = 0.322), while a substantial agreement was found between quantitative and qualitative elastography (kappa = 0.674). The results of the study provide evidence that the integration of elastography into BIRADS categorization can significantly improve the accuracy of breast cancer diagnosis in African women. Elastography enhanced lesion characterization, supporting more personalized and precise clinical management. Continued research is needed to fully integrate elastography into routine diagnostic workflows and understand its broader clinical implications in Africa.

Novel feature selection method for accurate breast cancer classification using Correlation coefficient and Modified GWO Algorithm

Breast cancer is perceived as the most common cause of mortality among women globally. Early detection of this disease is critical to reduce significantly the possibility of death. Machine learning techniques have been proved to be efficient and very successful for an accurate breast cancer diagnosis. In this paper, an efficient hybrid Feature Selection (FS) method named a Correlation technique-Modified Grey Wolf Optimizer (CMGWO) was proposed for accurate breast cancer classification based on dimensionality reduction. The suggested technique is based on two stages: the feature selection step and the classification step. Feature selection is the process of picking the most significant characteristics from a dataset. This stage is crucial in machine learning. Firstly, we focus on the filter method by using a Correlation technique for dimensionality reduction. This technique is intended to eliminate and reduce the number of features by selecting one feature from the other correlated features. Secondly, we use the Modified Grey Wolf Optimization algorithm (MGWO) to locate and determine the most significant features from uncorrelated features. After that, we use multiple classifiers to classify breast cancer disease based on the selected features. The Wisconsin Diagnostic Breast Cancer (WDBC) database was used to prove the performance of our proposed work. The experimental results show that the combination of the correlation method and MGWO for feature selection increases the accuracy rate of classification with a minimum number of features. The performances of different machine learning algorithms were evaluated, including Random Forest classifier (RF), Support Vector Machine (SVM) Classifier, and Naïve Bayes (NB) Classifier for the classification step. The suggested technique proves to be the best approach and reliable one among all studied approaches since it increases classification accuracy to 99.12\% obtained by CMGWO using Random Forest classifier and demonstrates its significance in detecting breast cancer.

Enhancing breast cancer diagnosis accuracy through genetic algorithm-optimized multilayer perceptron

Enhancing breast cancer diagnosis accuracy through genetic algorithm-optimized multilayer perceptron

Efficient Machine Learning and Deep Learning Techniques for Detection of Breast Cancer Tumor

The detection of cancer tumors is an essential component that has important consequences for the speedy involvement of medical professionals and the enhancement of patient outcomes. This review paper presents a complete study of the current body of research and methodology, as well as an in-depth assessment of the use of machine learning (ML) and deep learning (DL) in the detection of cancer tumors. In addition, the article gives a full analysis of the approaches involved. Machine learning and deep learning, which effectively handle ambiguity in the identification of malignant tumors, provide an alternative method for dealing with the complexity of brain tissue. This method is offered by a combination of machine learning and deep learning. The first part of the review draws attention to the significance of making an accurate diagnosis of breast cancer, highlights the limits of traditional diagnostic methods, and investigates the cutting-edge area of medical imaging technology. After that, it investigates the fundamentals of ML and DL and how they might be used to deal with the challenges that are inherent in the interpretation of complicated imaging data. In addition, the paper explores the ways in which models enhance the processes of feature extraction, picture segmentation, and classification in breast tumor detection systems.

Abstract PO2-13-12: Serum Thioredoxin 1 Enhances Breast Cancer Detection in Mammography and Breast Ultrasound, Including Dense Breasts

Abstract Background: Breast cancer (BC), when detected in its early stages, generally carries a more favorable prognosis than other types of cancer. Currently, the screening and early detection of breast cancer rely predominantly on image-oriented diagnostic methods. However, these methods inherently fall short in capturing the dynamic nature of cancer cells. Mammography has known limitations in clinical sensitivity, particularly in cases with high breast density. While breast ultrasound can mitigate some of these limitations, there remain unmet needs in this field. Previously, we reported the promising clinical performance (Sensitivity: 96.43%, Specificity: 97.32%) of serum thioredoxin 1 (Trx1) as a potential novel means for detecting breast cancer. In this study, we aim to evaluate the extent to which serum Trx1 can enhance the accuracy of breast cancer diagnosis, including in dense breasts, within the imaging-based diagnostic system powered by mammography and ultrasonography. Methods: We have generated monoclonal antibodies against Trx1 and developed an ELISA kit (DxMe® BC Kit, E&amp;S Healthcare, Korea) that quantifies Trx1 in serum. A total of 308 biopsy-confirmed breast cancer patients, who had undergone mammography prior to their final diagnosis, were recruited. The clinical information of these 308 patients was retrospectively examined and collected. The data from 254 individuals, who also had results from breast ultrasound, and 261 individuals, who had records of breast density, were analyzed collectively. Freshly collected blood was prepared as previously indicated, and then tested with the kit to determine the level of Trx1. All serum samples were measured twice, and statistical analyses were conducted using ROC analysis, one-way ANOVA, and unpaired t-tests. Results: Clinical sensitivity for BC detection was analyzed using the Trx1 levels of the 254 subjects who underwent both mammography and breast ultrasound. The respective sensitivities of mammography, breast ultrasound, and the DxMe® BC Kit were 72.83%, 92.91%, and 96.46%. With combined analysis of mammography, breast ultrasound, and Trx1, the sensitivity increased to 98.43% for mammography + breast ultrasound, and 98.82% for mammography + Trx1. When breast ultrasound + Trx1 was considered, the sensitivity rose to 99.61%. Likewise, the sensitivity of mammography + breast ultrasound + Trx1 was also measured at 99.61%. Among the 261 breast cancer patients with available information about breast density, 186 patients (71.3%) had dense breasts. The clinical sensitivity of mammography and Trx1 was specifically analyzed for these dense breast cases. Mammography demonstrated a sensitivity of 64.3%, while the DxMe® BC kit exhibited a sensitivity of 97.2%. When mammography and Trx1 were analyzed in parallel, sensitivity increased to 99.7%. Conclusion: This study demonstrated that the DxMe® BC kit, which quantifies serum Trx1 levels, can enhance the accuracy of conventional image-based diagnostics for breast cancer screening and early detection by more than 25%. This improvement in sensitivity was observed when mammography and breast ultrasound were each used in conjunction with Trx1, with no significant difference noted between these two combinations. Notably, in the case of dense breasts, the Trx1 test improved sensitivity by more than 30% compared to mammography. Given that sensitivity increases when mammography and Trx1 tests are used together, it showed that incorporating the Trx1 test alongside traditional mammography could significantly enhance diagnostic performance in dense breasts up to 35%. This approach has the potential to streamline the breast cancer diagnostic process, reduce time and cost, and improve the reliability of current breast cancer screening and early detection methods, regardless of breast density. Citation Format: Young Kim, Hyemi Ko, Yeri Lee, Keunkoo Shin, Jongam Song, Jeryoung Kim, Kyounghoon Suh, Jinsun Lee. Serum Thioredoxin 1 Enhances Breast Cancer Detection in Mammography and Breast Ultrasound, Including Dense Breasts [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-13-12.

Abstract PO1-07-03: An Accurate Breast Cancer Diagnosis Method Using a Multi-Feature Fusion Neural Network on Contrast-Enhanced Spectral Mammography

Abstract Objectives: Our study aims to develop an accurate and comprehensive deep neural network capable of classifying CESM images to aid in the early detection and diagnosis of breast cancer in clinical settings. Methods: We enrolled diagnostic CESM examinations conducted between January 1, 2019 and January 17, 2021. We developed and tested the performance of a multi-feature fusion network for breast lesion classification by combining low-energy (LE) and dual-energy subtracted (DES) images, dual-view, and bilateral information using a large and diverse CESM dataset. We have evaluated the ability of the proposed network to generalize on external datasets and the results were reported using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity. Results: In the study period 1973CESMs were included. Mean age was 53 years ± 12 (standard deviation). In the internal test dataset, the model with CESM (LE +DES) inputs combined not only bilateral information (left and right breasts) but also dualview information (CC and MLO), achieved best diagnosis performance with AUC of 0.96 [95% confidence interval (CI): 0.95–0.97], accuracy of 0.9 [95% confidence interval (CI): 0.88–0.92], sensitivity of 0.84 [95% confidence interval (CI): 0.80–0.88] and specificity of 0.93 [95% confidence interval (CI): 0.91–0.95], while the model with LE inputs only got an AUC of 0.94 [95% (CI): 0.93–0.95], accuracy of 0.88 [95% confidence interval (CI): 0.86–0.90], sensitivity of 0.79 [95% confidence interval (CI): 0.74–0.83] and specificity of 0.93 [95% confidence interval (CI): 0.91–0.95] (external dataset: an AUC of 0.90 [95% (CI): 0.85–0.94], accuracy of 0.84 [95% confidence interval (CI): 0.78–0.89], sensitivity of 0.77 [95% confidence interval (CI): 0.61–0.88] and specificity of 0.87 [95% confidence interval (CI):0.80–0.92]). Conclusion: CESM is a promising technique in breast cancer diagnosis due to its high feasibility and potential. The results demonstrate that left-right breast fusion and dual-view fusion are helpful for accurate diagnosis on CESM images. Specifically, dual-energy subtracted (DES) images generated by CESM improve diagnostic accuracy when compared to low-energy (LE) images alone. Keywords: Contrast-enhanced spectral mammography; Deep neural network; Breast cancer diagnosis; Multi-feature fusion Citation Format: Yipeng Song, Wei Jiang. An Accurate Breast Cancer Diagnosis Method Using a Multi-Feature Fusion Neural Network on Contrast-Enhanced Spectral Mammography [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-07-03.

BC-QNet: A quantum-infused ELM model for breast cancer diagnosis

The timely and accurate diagnosis of breast cancer is pivotal for effective treatment, but current automated mammography classification methods have their constraints. In this study, we introduce an innovative hybrid model that marries the power of the Extreme Learning Machine (ELM) with FuNet transfer learning, harnessing the potential of the MIAS dataset. This novel approach leverages an Enhanced Quantum-Genetic Binary Grey Wolf Optimizer (Q-GBGWO) within the ELM framework, elevating its performance. Our contributions are twofold: firstly, we employ a feature fusion strategy to optimize feature extraction, significantly enhancing breast cancer classification accuracy. The proposed methodological motivation stems from optimizing feature extraction for improved breast cancer classification accuracy. The Q-GBGWO optimizes ELM parameters, demonstrating its efficacy within the ELM classifier. This innovation marks a considerable advancement beyond traditional methods. Through comparative evaluations against various optimization techniques, the exceptional performance of our Q-GBGWO-ELM model becomes evident. The classification accuracy of the model is exceptionally high, with rates of 96.54 % for Normal, 97.24 % for Benign, and 98.01 % for Malignant classes. Additionally, the model demonstrates a high sensitivity with rates of 96.02 % for Normal, 96.54 % for Benign, and 97.75 % for Malignant classes, and it exhibits impressive specificity with rates of 96.69 % for Normal, 97.38 % for Benign, and 98.16 % for Malignant classes. These metrics are reflected in its ability to classify three different types of breast cancer accurately. Our approach highlights the innovative integration of image data, deep feature extraction, and optimized ELM classification, marking a transformative step in advancing early breast cancer detection and enhancing patient outcomes.

Deep Learning Paradigms for Breast Cancer Diagnosis: A Comparative Study on Wisconsin Diagnostic Dataset

Breast cancer is a highly common and life-threatening disease that affects people worldwide. Early and accurate diagnosis of breast cancer can enhance patients' prognosis and survival rate. This paper conducts a comparative examination of the Wisconsin Breast Cancer Diagnostic (WBCD) dataset by employing four distinct deep learning models: Feedforward Neural Network (FNN), Convolutional Neural Network (CNN), Long Short-Term Memory (LSTM), and Gated Recurrent Unit (GRU). The collection consists of 569 examples of Fine Needle Aspirate (FNA) photographs of breast cancers, with each case containing thirty parameters that define the features of the cell nuclei. By doing a comparative analysis of the advantages and disadvantages of the models, we will evaluate them based on their accuracy, precision, recall, and F1-score. Based on our research, CNN achieves the best level of accuracy at 98.25%, which is followed by GRU at 97.37%, FNN at 96.49%, and LSTM at 95.61%. It is determined that CNN is the most suitable model for this task and that deep learning models are valuable and encouraging tools for diagnosing breast cancer.

Improving Breast Cancer Diagnosis Accuracy by Particle Swarm Optimization Feature Selection

Breast cancer has been one of the leading causes of death among women in the world. Early detection of this disease can save patient’s lives and reduce mortality. Due to the large number of features involved in the diagnosis of this disease, the breast cancer diagnosis process can be time consuming. To reduce cost and time and improving accuracy of breast cancer diagnosis, this paper propose a feature selection algorithm based on particle swarm optimization (PSO) combined with machine learning methods for selection the most effective features for breast cancer diagnosis among all features. In order to evaluate the efficiency of the proposed feature selection method, it was tested on three most common breast cancer datasets available in the University of California, Irvine (UCI) repository named: Coimbra dataset (CD), Wisconsin Diagnostic Breast Cancer dataset (WDBC) and Wisconsin Prognostic Breast Cancer dataset (WPBC). In the Coimbra dataset with all its 9 features and without PSO feature selection algorithm the highest obtained accuracy was 87% by Support Vector Machine method, while with PSO feature selection algorithm the accuracy reached to 91% and the number of features was reduced from 9 to 4. In the WDBC dataset with all its 30 features and without PSO feature selection algorithm the highest obtained accuracy was 99% by Random Forest method, while with PSO feature selection algorithm the accuracy reached to 100% and the number of features was reduced from 30 to 19. In the WPBC dataset with all its 33 features and without PSO feature selection algorithm the highest obtained accuracy was 94% by Support Vector Machine method, while with PSO feature selection algorithm the accuracy reached to 96% and the number of features was reduced from 33 to 17. The results of this paper indicated that the proposed feature selection algorithm based on PSO algorithm can improve the accuracy of breast cancer diagnosis. While it has selected fewer and more effective features than the total number of features in the original datasets.

290 (PB-106) Poster - Improving the accuracy of breast cancer diagnosis in multi-protein signature markers using artificial intelligence algorithms

290 (PB-106) Poster - Improving the accuracy of breast cancer diagnosis in multi-protein signature markers using artificial intelligence algorithms

Uncertainty-aware deep learning-based CAD system for breast cancer classification using ultrasound and mammography images

ABSTRACT Breast cancer is one of the most common types of cancer in women. Early and accurate diagnosis of breast cancer can increase the treatment chances and decrease the mortality rate. Thus, the development of accurate and reliable Computer-Aided Diagnosis (CAD) systems using breast cancer images is an immediate priority for early diagnosis. Deep learning methods have had a widespread role in CAD systems. In spite of the advantages, most deep learning-based CADs cannot quantify the uncertainty of their predictions. Uncertainty in the predicted results from a CAD system might endanger people’s life in these crucial steps for breast cancer classification. Therefore, in this study, the Monte Carlo Dropout method is utilised as an uncertainty quantification method. Furthermore, differently from most existing studies, we present an uncertainty-aware deep learning model which can classify accurately from different types of images, namely, mammograms and ultrasound. The results show the proposed model achieved the accuracy of 99.95% in mammogram dataset, namely, DDSM and 98.40% and 91.34% in ultrasound datasets, namely, BUSM and BUSI, respectively. Finally, since we found the proposed model shows high uncertainty in misclassifications, we suggested to use the uncertainty values to find appropriate subsets for further inspection to increase the performance.

Modern visualization diagnostic methods of non-invasive breast carcinomas (review of literature)

Relevance. Breast carcinomas (BC) remain one of the most actual problems of modern oncology. According to statistics, the incidence of BC is steadily increasing, making it the most common cancer pathology among women. In this situation, the aspect of diagnosing BC at early, non-invasive stages, is certainly important, which still reduces mortality, increases the possibility of organ-preserving treatment, duration and quality of life of patients.The purpose of study. The purpose of study is to investigate and perform a comparative analysis of imaging techniques for the diagnosis of non-invasive breast carcinomas.Materials and methods. Modern Russian and foreign literature about the diagnosis of non-invasive breast carcinomas was analyzed. Publications not older than 7 years published in specialized medical editions were taken into account Results. Not only main, but also new, promising imaging modalities that are not currently part of routine practice were analyzed. The main imaging patterns in non-invasive breast carcinomas (DCIS, LCIS and Paget's breast cancer), feasibility and prognostic value of certain diagnostic methods in different nosologies of this disease were also discussed.Conclusion. The statistics provided explain the importance of breast carcinomas problem, as well as the relevance of its diagnosis at non-invasive stages. According to the authors, the issue of accurate diagnosis of breast cancer in situ is subject to further discussion and study, but we would like to note that when non-invasive breast carcinoma is suspected and doubtful imaging results are obtained, one should not limit oneself only to routine methods of imaging studies, but expand further diagnostic tactics until accurate results are obtained and a final diagnosis is made.

Empowering breast cancer diagnosis and radiology practice: advances in artificial intelligence for contrast-enhanced mammography.

Artificial intelligence (AI) applications in breast imaging span a wide range of tasks including decision support, risk assessment, patient management, quality assessment, treatment response assessment and image enhancement. However, their integration into the clinical workflow has been slow due to the lack of a consensus on data quality, benchmarked robust implementation, and consensus-based guidelines to ensure standardization and generalization. Contrast-enhanced mammography (CEM) has improved sensitivity and specificity compared to current standards of breast cancer diagnostic imaging i.e., mammography (MG) and/or conventional ultrasound (US), with comparable accuracy to MRI (current diagnostic imaging benchmark), but at a much lower cost and higher throughput. This makes CEM an excellent tool for widespread breast lesion characterization for all women, including underserved and minority women. Underlining the critical need for early detection and accurate diagnosis of breast cancer, this review examines the limitations of conventional approaches and reveals how AI can help overcome them. The Methodical approaches, such as image processing, feature extraction, quantitative analysis, lesion classification, lesion segmentation, integration with clinical data, early detection, and screening support have been carefully analysed in recent studies addressing breast cancer detection and diagnosis. Recent guidelines described by Checklist for Artificial Intelligence in Medical Imaging (CLAIM) to establish a robust framework for rigorous evaluation and surveying has inspired the current review criteria.